Leqselvi launch delay due to litigation
Incyte filed a preliminary injunction motion to block Leqselvi launch; outcome uncertain and could delay revenue contribution.
SUNPHARMA / Q1-FY25 / risks
Keep the risk register visible.
Sunpharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Halol plant re-audit timeline uncertain
Management plans to request FDA re-audit once ready, but no specific timeline provided; pending approvals may impact U.S. generic pipeline.
U.S. generic revenue flat despite Revlimid contribution
U.S. generic sales were flat sequentially; Revlimid contribution was not large this quarter, and sustainability is uncertain.